Patient stratification and risk related treatment of NMIBC
In 2021 the EAU Guidelines panel proposed a new risk stratification using individual data from a large series of Ta-T1 NMIBCs. The novelty of this “4 risk categories” system, able to stratify patients with a progression rate ranging from 1% in the “low risk” up to 40% in the “very high risk”, its use in clinical practice along with the important implications on treatment decision making will be the core of the discussion.
|Organiser||European School of Urology (ESU)|
|Duration||Approx. 60 minutes|
Additional tools able to predict recurrence rate and individual prognosis following treatment will also be addressed in a 1 hour interactive discussion with NMIBC guideline panel members.
Prof. P. Gontero (IT)
Mr. H. Mostafid (GB)
Prof. Dr. B.W.G. Van Rhijn (NL)
Contact our organiser
European School of Urology (ESU)